GoodRx Q3 2025 TL;DR Summary
GoodRx reported highly mixed results for Q3 2025, characterized by significant industry disruption masking strong year-to-date profitability improvement and aggressive capital deployment.
Financial Highlights: Q3 Net Income sharply declined to $1.1 million (0.6% margin), resulting in $0.00 Basic/Diluted EPS for the quarter, though Adjusted EBITDA remained strong at $66.3 million. Conversely, nine-month (YTD) Net Income more than doubled to $25.0 million (4.2% margin), yielding YTD EPS of $0.07. Liquidity declined significantly; Cash and equiv
...